Beam Therapeutics is trading 4.38% higher at $25.50 in pre-market after announcing initial Phase 1/2 BEAM-301 data on October 13, 2026; sources do not directly attribute the rise to the announcement. - Both evaluable patients in the 40 mg cohort achieved at least 15 hours of controlled fasting, a promising result for the investigational GSDIa treatment. - The trial included six patients; all experienced at least one treatment-related adverse event. Beam plans to present the data at the ESGCT congress later this month. - Available market context showed only modestly positive index moves.